HY-P99225-5mg
|
MedChemexpress LLC
|
Mirvetuximab [CAS 1453084-36-0]
|
|
Cancer-programmed cell death
|
|
HY-132258-1mg
|
MedChemexpress LLC
|
Mirvetuximab soravtansine [CAS 1453084-37-1]
|
|
Cancer-programmed cell death
|
|
HY-132258-5mg
|
MedChemexpress LLC
|
Mirvetuximab soravtansine [CAS 1453084-37-1]
|
|
Cancer-programmed cell death
|
|
HY-P99253-1mg
|
MedChemexpress LLC
|
MogaMu lizumab [CAS 1159266-37-1]
|
|
COVID-19-anti-virus
|
|
HY-P99253-10mg
|
MedChemexpress LLC
|
MogaMu lizumab [CAS 1159266-37-1]
|
|
COVID-19-anti-virus
|
|
HY-P99253-5mg
|
MedChemexpress LLC
|
MogaMu lizumab [CAS 1159266-37-1]
|
|
COVID-19-anti-virus
|
|